trending Market Intelligence /marketintelligence/en/news-insights/trending/9b3q8ldfm3oybc_qifpaaa2 content esgSubNav
In This List

Court upholds Boston Scientific's heart valve patent over Edwards Lifesciences


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises

Court upholds Boston Scientific's heart valve patent over Edwards Lifesciences

Boston Scientific Corp. said a U.S. district court has ruled in its favor in a patent dispute, finding that Edwards Lifesciences Corp.'s Sapien 3 transcatheter heart valve infringed on one of its patents.

The jury in the U.S. District Court for the District of Delaware said that Irvine, Calif.-based Edwards Lifesciences owes Boston Scientific $35 million in infringement damages through the end of 2016. Additional damages along with interest will be determined later.

The jury also found that Boston Scientific's Lotus aortic valve system does not infringe on Edwards Lifesciences' Spenser patents.

Marlborough, Mass.-based Boston Scientific filed a lawsuit in 2016 alleging that Sapien 3 infringed on patents for technology used in Boston Scientific's Lotus valve system.

The court win is not the first for Boston Scientific regarding the Lotus system. The company has also received favorable rulings from courts in the U.K. and Germany in a litigation battle that spans several countries.

According to Edwards Lifesciences, the company does not expect to pay the infringement damages as the U.S. Patent and Trademark Office ruled in its favor, saying that all the claims asserted against Edwards Lifesciences were invalid. The company plans to appeal the decision.